Truncating CHEK2 variants have also been shown to confer a slightly increased risk for gastric cancer, kidney cancer, sarcoma, prostate cancer [10], and colorectal cancer [11], with the relative risk for the latter estimated to be 1.88 [52]. This evidence concerns the gene CHEK2 and gastric cancer.